The MEA biologics and biosimilar market is expected to enjoy a valuation of US$ 512.6 Million in the year 2023, and further expand at a CAGR of 5.5% to reach a valuation of ~US$ 875.6 Million by the year 2033. According to a recent study by Future Market Insights, adalimumab in the drug segment is leading the market with a share of about 36.7% in the year 2022, within the MEA market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 485.9 Million |
| Market Value 2033 | US$ 875.6 Million |
| CAGR 2023 to 2033 | 5.5% |
| Market Share of Top 5 Countries | 87.2% |
| Key Market Players | AbbVie Inc., Eisai Co Ltd, Zydus Cadila(Cadila Healthcare), Amneal Pharmaceuticals, Inc., Pfizer Inc., Celltrion, Inc., Coherus BioSciences, Inc., F. Hoffmann–La Roche Ltd (Genentech, Inc.), Alexion(AstraZeneca), Johnson & Johnson, Amgen, and Hikma pharmaceuticals plc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for MEA biologics and biosimilar market was approximately 3.1% of the overall ~US$ 15.4 Billion global biologics and biosimilar market in 2021.
The most common cancers are breast cancer, lung and bronchus, colon and rectum, prostate, stomach, liver, cervix uteri, oesophagus, thyroid, and bladder.
to improve cancer patient care and ensure sure they have access to more effective, convenient, and affordable treatment options. MEA's expansion in oncology innovation is being fuelled by a flurry of new, oncology–focused biotech businesses and increased cancer research.
due to the rising incidence of numerous cancers, the market for biosimilar drugs is anticipated to expand in this region.
Manufacturers of biologics are adopting various strategies to respond to potential entrants in biosimilars.
Pharmaceutical manufacturers are concentrating on ways to broaden and improve formulations, dosing, expression systems, and delivery mechanisms.
For MabThera, for instance, Roche created a novel subcutaneous formulation that reduces treatment time from 2.5 hours to 5 minutes. This can enhance patient adherence and healthcare results.
To remain competitive and ensure a robust product pipeline, leading biopharmaceutical companies are continuing to focus on the development of innovative drugs associated with regular treatments and technologically advanced healthcare solutions to increase the adoption rate.
Over the next ten years, originator biologicals' patents and other intellectual property rights will expire, thus creating opportunities for biosimilars to enter the market and raising industry competition.
Governments using biosimilars as a less expensive alternative to cut healthcare costs is fueling demand. The value of the industry is also rising due to government initiatives, strategic partnerships, and an increase in the incidence of new diseases.
The market share of biosimilars is also growing as a result of deeper penetration into emerging markets in MEA countries.
New product approvals are expected to drive the market and provide prospects for manufacturers to present a diverse and innovative product portfolio.
There are several clinical trials ongoing for the development of biosimilars that have proved to be a better alternative to biologics. For instance, manufacturers are focused on the development of trastuzumab and rituximab biosimilars; some of these are approved, and others are still in the development stage.
Thus, the switch to biosimilars has the potential to have a significant impact. Moreover, developing nations require biosimilar drugs, as compounding pharmacies are extremely rare in these countries, which creates a huge market for manufacturers of biosimilars
Thus, owing to the forenamed factors, the MEA biologics and biosimilar market is expected to grow at a CAGR of 5.5% during the forecast period from 2023 to 2033.
Ustekinumab surpassed other medications in terms of annual increases in medical inflation-adjusted prices. Innovative strategies, such as the creation of biosimilars to improve patient access to care, are essential for reducing cost growth above inflation.
Global industry leaders are developing extended indications for already licensed biologics. The strategic approach involves the extension of the indication by conducting additional clinical investigations on the licensed biologics candidate.
The most advanced portfolios of biologics and biosimilars are held by early market leaders including AbbVie, Eisa Co Ltd., and Janssen Pharmaceuticals, a division of Johnson & Johnson.
According to WHO (2022), Non-communicable disease mortality is dramatically increasing in Middle Eastern and African (MEA) nations. 74% of all deaths in MEA are caused due to non-communicable diseases, which cause more than 38 million deaths annually worldwide.
For non-communicable diseases with a high prevalence, like cancer, diabetes, and rheumatoid arthritis, biosimilar drugs are readily available across major therapeutic categories.
The global picture of biologic therapy access is still uneven across high–income and low-income nations, and it reflects other inequalities in infrastructure, infrastructure, and economy.
The reinvestment of savings related to lower costs on biosimilar medicines compared to innovator biologic drugs has resulted in improved and more equitable access to biologic therapies and to healthcare in general in various countries.
This can be considered an opportunistic factor for the manufacturers operating within the MEA biologics and biosimilar market.
Principal Consultant
The number of manufacturers that can successfully launch biosimilar pharmaceuticals on the market in various nations throughout the world is constrained by prolonged, expensive, ineffective, and diverse regulatory approval procedures.
Despite the approval of the WHO Similar Biotherapeutic Product (SBP) guideline in 2009, several countries have failed to actively accept and execute the WHO's recommendations for biosimilar medicines.
There are a variety of off-patent biologic drugs available in low- and middle-income countries (LMICs), some of which are quality-assured biosimilars by WHO guidelines, but others are not, creating complexity. The level of regulatory maturity varies substantially throughout the Middle East and Africa (MEA) region.
Thus, stringent government regulations can be a major hindrance that can restrict the market growth in MEA.
Biologic therapeutics are not always accessible to eligible patients, due to high co–payments, limited or non–existent utilization, and/or lack of reimbursement for the original biologic product.
A significant portion of the population in the United Arab Emirates (UAE) is covered by private payers. The complexity of providing affordable access is increased by the growth of private payers and health insurance programs.
Many physicians prefer to be loyal to the original pharmaceutical manufacturers, whose products they are familiar with and have used for years. The utilization of biosimilar medications remains limited even when a payer adds one to their regimen.
Therefore, the lack of reimbursement for the costlier biologics can limit the use of biologics in the MEA region.
The mentioned factors collectively propose an adverse effect on the developmental growth of the MEA biologics and biosimilar market.
The KSA accounted for around 34.1% market share in the MEA biologics and biosimilar market in 2022, and a similar trend is expected over the forecast period.
KSA is evolving towards a more favorable environment for significant uptake of biosimilars, taking into account growing government emphasis on enhancing patient access to medications, financial restrictions, and the presence of a regulatory framework. The availability of medications in the KSA biologics and biosimilar market has increased as a result of expectations that KSA will be the most lucrative nation in the biologics and biosimilar industry.
In 2022, UAE held the highest market share of about 19.3% 2022 in the UAE biologics and biosimilar market.
There has been increased investment by local and regional companies in the biosimilar space considering the untapped opportunity UAE in partnership with Biocad, Sedico. Anticancer biologics are also used in the region because cancer is now the second most frequent cause of death, after heart disease.
Kuwait held approximately 14.8% market share in the MEA biologics and biosimilar market in 2022. Because of the expanding population and rising medication demand, Kuwait is developing quickly. Nowadays, the perspectives of stakeholders, physicians, and pharmacists have changed. Their strong conviction in generics and biosimilars is rising as a result of their low cost and convenient administration manner.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The adalimumab segment in the drug category of the MEA biologics and biosimilar market accounts for a market share of about 36.7% in the MEA market in 2022.
Patients with moderate to severe active psoriatic arthritis benefit from adalimumab treatment, which lessens joint and skin symptoms of the condition as well as disability brought on by joint destruction. Adalimumab shows a quick onset of effect and continued efficacy over the course of treatment.
The TNF Alfa Inhibitors in the drug class segment have become more and more popular, accounting for the greatest proportion of 29.1% in 2022. TNF-alpha inhibitors can be helpful for a variety of inflammatory conditions, including psoriasis, spondyloarthritis, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). TNF-alpha inhibitors offer a targeted approach in contrast to the non-specific immunosuppressive medications that are frequently utilised to treat the bulk of inflammatory diseases.
The subcutaneous dosage form segment accounts for around 52.2% of the global market share in 2022. Individuals or healthcare professionals utilizing a variety of different drug delivery systems can administer therapeutics subcutaneously. SC administration lowers the fixed expenses associated with running a medical facility because it allows patients to self-administer in outpatient or home settings. The anatomical infusion location is flexible with SC administration, and alternatives include the stomach, thighs, and backs of the arms.
Arthritis in the indication segment accounts for a global market share of around 28.2% in 2022. A person's total function and mobility may be impacted by arthritis, which may lead to activity and other limits. According to recent studies, the likelihood of developing arthritis increases with age, body mass index, physical inactivity, and declining physical and mental health. Adults who are unable to work, incapacitated, or have fair or poor self–rated health have the highest rates of arthritis.
With 85.1% of the market share, the institutional sales segment in the distribution channel category dominated the MEA biologics and biosimilar market in 2022. Institutional sales leaders from the biotech, pharmaceutical, and medical device sectors collaborate with GPOs, ACOs, and IDNs to launch successful products across the country, thus propelling segment value.
The leading players invest in several product launches, expansions, partnerships, mergers, and acquisitions to increase their market share globally and enhance their business strategies. The major companies in the MEA biologics and biosimilar market have embraced these as their top–tier primary promotional methods.
Hikma Pharmaceuticals announced in July 2022 that it has signed a marketing agreement for Celltrion's YuflymaTM drug.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the MEA biologics and biosimilar market space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value & Volume (Units) |
| Key Region Covered | Middle East & Africa |
| Key Countries Covered | UAE, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, KSA, Iran, and Palestine |
| Key Market Segments Covered | Drug, Drug Class, Dosage Form, Indication, Distribution Channel and Country |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The overall market value is estimated to be around US$ 875.6 million in 2023.
AbbVie, Eisai, and Zydus Cadila are some top service providers in the MEA market.
KSA leads and accounted for 34.1% of the total sales in MEA in 2022.
Improving patient access to healthcare and reducing cost growth above inflation.
The adalimumab drug segment accounted for 36.7% of the regional market in 2022.
1. Executive Summary | MEA Biologics and Biosimilar Market 1.1. MEA Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Drug Innovation / Development Trends 4. Key Success Factors 4.1. Regulatory Scenario 4.2. Pipeline Assessment 4.3. Key Marketing & Promotional Strategies Adopted by Companies 4.4. PESTLE Analysis 4.5. Porter’s Analysis 4.6. Value Chain Analysis 5. Market Background 5.1. Macro–Economic Factors 5.1.1. MEA GDP Growth Outlook 5.1.2. MEA Healthcare Expenditure 5.1.3. Global Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increase in Research and Development Funding and Grants 5.2.2. High Demand for Biologics 5.2.3. Surge in Research Collaborations for the Development of Drugs 5.2.4. New Product Launch 5.2.5. Regulatory Approvals 5.2.6. Cost of Drugs 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Drug 6.1.2. Revenue By Drug Class 6.1.3. Revenue By Dosage Form 6.1.4. Revenue By Indication 6.1.5. Revenue By Distribution Channel 6.1.6. Revenue By Country 6.2. 2021 Market Scenario 7. MEA Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast 2023 to 2033 7.1. Historical Market Volume (Units) Analysis, 2017 to 2022 7.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 7.2.1. Y–o–Y Growth Trend Analysis 8. MEA Market - Pricing Analysis 8.1. MEA Average Pricing Analysis Benchmark 8.2. Pricing Assumptions 9. MEA Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033 9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 9.2. Current Market Value (US$ Million) Forecast 2023 to 2033 9.2.1. Y–o–Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2023 to 2033 10.3.1. Adalimumab 10.3.2. Bevacizumab 10.3.3. Trastuzumab 10.3.4. Ustekinumab 10.3.5. Golimumab 10.3.6. Eculizumab 10.3.7. Rituximab 10.4. Market Attractiveness Analysis By Drug 11. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis By Drug Class, 2023 to 2033 11.3.1. Antirheumatics 11.3.2. TNF Alfa Inhibitors 11.3.3. VEGF/VEGFR Inhibitors 11.3.4. HER2 Inhibitors 11.3.5. Selective Immunosuppressants 11.3.6. Interleukin Inhibitors 11.4. Market Attractiveness Analysis By Drug Class 12. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Dosage Form 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis By Dosage Form, 2023 to 2033 12.3.1. Subcutaneous 12.3.2. Intravenous 12.4. Market Attractiveness Analysis By Dosage Form 13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis By Indication, 2023 to 2033 13.3.1. Cancer 13.3.2. Arthritis 13.3.2.1. Rheumatoid 13.3.2.2. Psoriatic 13.3.2.3. Others 13.3.3. Skin Disorders 13.3.3.1. Plaque-Type Psoriasis 13.3.3.2. Hidradenitis Suppurativa 13.3.4. Inflammatory Bowel Disease (IBD) 13.3.4.1. Crohn's Disease 13.3.4.2. Ulcerative Colitis 13.3.5. Rare Disease 13.3.6. Others 13.4. Market Attractiveness Analysis By Indication 14. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis By Distribution Channel, 2023 to 2033 14.3.1. Institutional Sales 14.3.1.1. Hospitals 14.3.1.2. Specialty Clinics 14.3.1.3. Cancer Research Centers 14.3.2. Retail Sales 14.3.2.1. Retail Pharmacies 14.3.2.2. Mail Order Pharmacies/Online Sales 14.4. Market Attractiveness Analysis By Distribution Channel 15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis, By Country, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis By Country, 2023 to 2033 15.3.1. UAE 15.3.2. Kuwait 15.3.3. Qatar 15.3.4. Bahrain 15.3.5. Oman 15.3.6. Lebanon 15.3.7. Jordan 15.3.8. Palestine 15.3.9. Iraq 15.3.10. KSA 15.3.11. Iran 15.4. Market Attractiveness Analysis By Country 16. UAE Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 16.3.1. By Drug 16.3.2. By Drug Class 16.3.3. By Dosage Form 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Drivers and Restraints - Impact Analysis 16.5. Market Attractiveness Analysis By UAE 17. Kuwait Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 17.3.1. By Drug 17.3.2. By Drug Class 17.3.3. By Dosage Form 17.3.4. By Indication 17.3.5. By Distribution Channel 17.4. Drivers and Restraints - Impact Analysis 17.5. Market Attractiveness Analysis By Kuwait 18. Qatar Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 18.3.1. By Drug 18.3.2. By Drug Class 18.3.3. By Dosage Form 18.3.4. By Indication 18.3.5. By Distribution Channel 18.4. Drivers and Restraints - Impact Analysis 18.5. Market Attractiveness Analysis By Qatar 19. Bahrain Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 19.3.1. By Drug 19.3.2. By Drug Class 19.3.3. By Dosage Form 19.3.4. By Indication 19.3.5. By Distribution Channel 19.4. Drivers and Restraints - Impact Analysis 19.5. Market Attractiveness Analysis By Bahrain 20. Oman Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 20.3.1. By Drug 20.3.2. By Drug Class 20.3.3. By Dosage Form 20.3.4. By Indication 20.3.5. By Distribution Channel 20.4. Drivers and Restraints - Impact Analysis 20.5. Market Attractiveness Analysis By Oman 21. Lebanon Market Analysis 2017 to 2022 Forecast 2023 to 2033 21.1. Introduction 21.2. Pricing Analysis 21.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 21.4. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 21.4.1. By Drug 21.4.2. By Drug Class 21.4.3. By Dosage Form 21.4.4. By Indication 21.4.5. By Distribution Channel 21.5. Drivers and Restraints - Impact Analysis 21.6. Market Attractiveness Analysis By Lebanon 22. Jordan Market Analysis 2017 to 2022 and Forecast 2023 to 2033 22.1. Introduction 22.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 22.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 22.3.1. By Drug 22.3.2. By Drug Class 22.3.3. By Dosage Form 22.3.4. By Indication 22.3.5. By Distribution Channel 22.4. Drivers and Restraints - Impact Analysis 22.5. Market Attractiveness Analysis By Jordan 23. Palestine Market Analysis 2017 to 2022 and Forecast 2023 to 2033 23.1. Introduction 23.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 23.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 23.3.1. By Drug 23.3.2. By Drug Class 23.3.3. By Dosage Form 23.3.4. By Indication 23.3.5. By Distribution Channel 23.4. Drivers and Restraints - Impact Analysis 23.5. Market Attractiveness Analysis By Palestine 24. Iraq Market Analysis 2017 to 2022 and Forecast 2023 to 2033 24.1. Introduction 24.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 24.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 24.3.1. By Drug 24.3.2. By Drug Class 24.3.3. By Dosage Form 24.3.4. By Indication 24.3.5. By Distribution Channel 24.4. Drivers and Restraints - Impact Analysis 24.5. Market Attractiveness Analysis By Iraq 25. KSA Market Analysis 2017 to 2022 and Forecast 2023 to 2033 25.1. Introduction 25.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 25.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 25.3.1. By Drug 25.3.2. By Drug Class 25.3.3. By Dosage Form 25.3.4. By Indication 25.3.5. By Distribution Channel 25.4. Drivers and Restraints - Impact Analysis 25.5. Market Attractiveness Analysis By KSA 26. Iran Market Analysis 2017 to 2022 and Forecast 2023 to 2033 26.1. Introduction 26.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 26.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033 26.3.1. By Drug 26.3.2. By Drug Class 26.3.3. By Dosage Form 26.3.4. By Indication 26.3.5. By Distribution Channel 26.4. Drivers and Restraints - Impact Analysis 26.5. Market Attractiveness Analysis By Iran 27. Market Structure Analysis 27.1. Market Analysis by Tier of Companies 27.2. Market Share Analysis of Top Players 27.3. Market Presence Analysis 27.3.1. Regional Footprint Analysis 27.3.2. Product Footprint Analysis 27.3.3. Channel Footprint Analysis 28. Competition Analysis 28.1. Competition Dashboard 28.2. Competition Benchmarking 28.3. Competition Deep Dive 28.3.1. AbbVie Inc. 28.3.1.1. Overview 28.3.1.2. Product Portfolio 28.3.1.3. Key Financials 28.3.1.4. SWOT Analysis 28.3.1.5. Sales Footprint 28.3.1.6. Strategy Overview 28.3.1.7. Key Developments 28.3.1.7.1. Marketing Strategies 28.3.1.7.2. Product Strategies 28.3.1.7.3. Channel Strategies 28.3.2. Eisai Co Ltd 28.3.2.1. Overview 28.3.2.2. Product Portfolio 28.3.2.3. Key Financials 28.3.2.4. SWOT Analysis 28.3.2.5. Sales Footprint 28.3.2.6. Strategy Overview 28.3.2.7. Key Developments 28.3.2.7.1. Marketing Strategies 28.3.2.7.2. Product Strategies 28.3.2.7.3. Channel Strategies 28.3.3. Zydus Cadila 28.3.3.1. Overview 28.3.3.2. Product Portfolio 28.3.3.3. Key Financials 28.3.3.4. SWOT Analysis 28.3.3.5. Sales Footprint 28.3.3.6. Strategy Overview 28.3.3.7. Key Developments 28.3.3.7.1. Marketing Strategies 28.3.3.7.2. Product Strategies 28.3.3.7.3. Channel Strategies 28.3.4. AMillioneal Pharmaceuticals, Inc. 28.3.4.1. Overview 28.3.4.2. Product Portfolio 28.3.4.3. Key Financials 28.3.4.4. SWOT Analysis 28.3.4.5. Sales Footprint 28.3.4.6. Strategy Overview 28.3.4.7. Key Developments 28.3.4.7.1. Marketing Strategies 28.3.4.7.2. Product Strategies 28.3.4.7.3. Channel Strategies 28.3.5. Pfizer Inc. 28.3.5.1. Overview 28.3.5.2. Product Portfolio 28.3.5.3. Key Financials 28.3.5.4. SWOT Analysis 28.3.5.5. Sales Footprint 28.3.5.6. Strategy Overview 28.3.5.7. Key Developments 28.3.5.7.1. Marketing Strategies 28.3.5.7.2. Product Strategies 28.3.5.7.3. Channel Strategies 28.3.6. Amgen Inc. 28.3.6.1. Overview 28.3.6.2. Product Portfolio 28.3.6.3. Key Financials 28.3.6.4. SWOT Analysis 28.3.6.5. Sales Footprint 28.3.6.6. Strategy Overview 28.3.6.7. Key Developments 28.3.6.7.1. Marketing Strategies 28.3.6.7.2. Product Strategies 28.3.6.7.3. Channel Strategies 28.3.7. Celltrion, Inc. 28.3.7.1. Overview 28.3.7.2. Product Portfolio 28.3.7.3. Key Financials 28.3.7.4. SWOT Analysis 28.3.7.5. Sales Footprint 28.3.7.6. Strategy Overview 28.3.7.7. Key Developments 28.3.7.7.1. Marketing Strategies 28.3.7.7.2. Product Strategies 28.3.7.7.3. Channel Strategies 28.3.8. Coherus BioSciences, Inc. 28.3.8.1. Overview 28.3.8.2. Product Portfolio 28.3.8.3. Key Financials 28.3.8.4. SWOT Analysis 28.3.8.5. Sales Footprint 28.3.8.6. Strategy Overview 28.3.8.7. Key Developments 28.3.8.7.1. Marketing Strategies 28.3.8.7.2. Product Strategies 28.3.8.7.3. Channel Strategies 28.3.9. F. Hoffmann–La Roche Ltd 28.3.9.1. Overview 28.3.9.2. Product Portfolio 28.3.9.3. Key Financials 28.3.9.4. SWOT Analysis 28.3.9.5. Sales Footprint 28.3.9.6. Strategy Overview 28.3.9.7. Key Developments 28.3.9.7.1. Marketing Strategies 28.3.9.7.2. Product Strategies 28.3.9.7.3. Channel Strategies 28.3.10. Alexion 28.3.10.1. Overview 28.3.10.2. Product Portfolio 28.3.10.3. Key Financials 28.3.10.4. SWOT Analysis 28.3.10.5. Sales Footprint 28.3.10.6. Strategy Overview 28.3.10.7. Key Developments 28.3.10.7.1. Marketing Strategies 28.3.10.7.2. Product Strategies 28.3.10.7.3. Channel Strategies 28.3.11. Janssen Biotech, Inc. 28.3.11.1. Overview 28.3.11.2. Product Portfolio 28.3.11.3. Key Financials 28.3.11.4. SWOT Analysis 28.3.11.5. Sales Footprint 28.3.11.6. Strategy Overview 28.3.11.7. Key Developments 28.3.11.7.1. Marketing Strategies 28.3.11.7.2. Product Strategies 28.3.11.7.3. Channel Strategies 28.3.12. Hikima Pharmaceuticals plc. 28.3.12.1. Overview 28.3.12.2. Product Portfolio 28.3.12.3. Key Financials 28.3.12.4. SWOT Analysis 28.3.12.5. Sales Footprint 28.3.12.6. Strategy Overview 28.3.12.7. Key Developments 28.3.12.7.1. Marketing Strategies 28.3.12.7.2. Product Strategies 28.3.12.7.3. Channel Strategies 29. Assumptions and Acronyms Used 30. Research Methodology
Explore Healthcare Insights
View Reports
MEA Biologics and Biosimilar Market
